Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7268489 add-on to ocrelizumab in progressive multiple sclerosis
2025-521636-10-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing RO7268489 + ocrelizumab with RO7268489 placebo + ocrelizumab (2 arms). Primary endpoint: Time to first composite confirmed disability progression at 12 weeks. Planned start Feb 2026; status: authorised.
02
Drugs
RO7268489
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2025-521636-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521636-10-00.